Human T-cell leukemia virus type 1: oncogenic potential and vaccine development strategies

Human T-cell leukemia virus type 1: oncogenic potential and vaccine development strategies

The human T-cell lymphotropic virus type 1 (HTLV-1) is a highly oncogenic retrovirus recognized as the causative agent of adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Among the key risk factors for ATLL development are high proviral l...

Full description

Saved in:
Bibliographic Details
Main Authors: Jorge Vasconez-Gonzalez, Isaac A. Suárez-Sangucho, Esteban Acosta-Muñoz, Luis Paz y Miño, Domenic Borja-Mendoza, John Altamirano Alexander-Castillo, Julia Saa, Natasha Salazar-Calvopiña, Paúl Cárdenas, Andrés López-Cortés, Esteban Ortiz-Prado
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Cellular and Infection Microbiology
Subjects:
HTLV-1
human T-cell leukemia virus type 1
oncogenesis
viral oncogenes
immune evasion
retrovirus
Online Access:https://www.frontiersin.org/articles/10.3389/fcimb.2025.1587802/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The human T-cell lymphotropic virus type 1 (HTLV-1) is a highly oncogenic retrovirus recognized as the causative agent of adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Among the key risk factors for ATLL development are high proviral load, reduced anti-Tax immune responses, and elevated levels of soluble interleukin-2 receptor. Unlike classical oncogenic viruses, HTLV-1 does not encode proto-oncogenes but instead drives cellular transformation through a combination of mechanisms, including viral gene dysregulation, chromatin remodeling, epigenetic reprogramming, persistent clonal expansion, immune evasion, and RNA-based modifications. Despite growing understanding of these molecular pathways, an effective prophylactic vaccine against HTLV-1 remains unavailable. However, several vaccine strategies including viral vector platforms, mRNA-based candidates, peptide vaccines, and dendritic cell-based approaches have shown promise in preclinical models. In this review, we provide a comprehensive synthesis of current knowledge on HTLV-1 oncogenesis, highlight the roles of viral proteins such as Tax and HBZ in immune evasion, and critically examine the state of vaccine development efforts aimed at controlling this neglected human retrovirus.
ISSN:2235-2988

Similar Items